Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2255-2261

  Anton, Antonio ^a   Lluch, Ana ^b   Casado, Antonio ^c   Provencio, Mariano ^d   Muñoz, Montserrat ^e   Lao, Juan ^a   Bermejo, Begoña ^b   Paules, Ana B ^f   Gayo, Javier ^f   Martin, Miguel ^c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Capecitabine; Metastatic breast cancer; Oral chemotherapy; Vinorelbine

Indexed keywords

CAPECITABINE; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; VINBLASTINE;

EID: 77955082699     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50(7): 7-33, 2000.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717, 2005. (Pubitemid 40719106)
3. Nowak AK, Wilcken NR, Stockier MR, Hamilton A and Ghersi D: Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5(6): 372-380, 2004.
4. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP and Meininger V: Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 76(2 Suppl 4): 9-14, 1989.
5. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P and Marty M: Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14(12): 3097-3104, 1996.
6. Romero Acuna L, Langhi M, Perez J, Romero Acuna J, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodriguez R, Barbieri M and Leone B: Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17(1): 74-81, 1999.
7. Fumoleau P, Fety R, Delecroix V, Perrocheau G and Azli N: Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology (Williston Park) 11(6 Suppl 6): 29-31, 1997. (Pubitemid 27319561)
8. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P and Tursz T: Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 72(9): 1764-1770, 1994. (Pubitemid 24349375)
9. Sorensen P, Hoyer M, Jakobsen A, Malmstrom H, Havsteen H and Bertelsen K: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 81(1): 58-62, 2001.
10. Liu G, Franssen E, Fitch MI and Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1): 110-115, 1997.
11. Bonneterre J, Chevalier B, Focan C, Mauriac L and Piccart M: Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 12(12): 1683-1691, 2001.
12. Soulas F, Danel P and Barbier M: Open label, multicentre randomised phase II trial of oral vinorelbine versus intravenous vinorelbine in advance/metastatic non-small lung cancer. Final report. Institute de Recherche Pierre Fabre, Report PM259 CACO10; 1999.
13. Trillet-Lenoir V, Brandely M and Danel P: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. Internal report: Pierre Fabre Medicament. Report PM259 CA C007; 1999.
14. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5): 330-338, 2003. (Pubitemid 37328853)
15. O'Shaughnessy J: Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 38(Suppl 2): 10-14, 2002.
16. Ershler WB: Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11(4): 325-335, 2006.
17. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S and Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12): 2812-2823, 2002.
18. Walko CM and Lindley C: Capecitabine: a review. Clin Ther 27(1): 23-44, 2005.
19. Sawada N, Fujimoto-Ouchi K, Ishikawa T, Tanaka Y and Ishituka H: Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 43: 1088 (Abstr 5388), 2002.
20. Hess D, Thurlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, Rufener B, Castiglione-Gertsch M and Goldhirsch A: Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial. Ann Oncol 15(12): 1760-1765, 2004.
21. Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S and Vanhoefer U: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16(1): 64-69, 2005.
22. Ghosn M, Kattan J, Farhat F, Younes F and Gasmi J: Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26(3B): 2451-2456, 2006. (Pubitemid 43980216)
23. Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, Monticelli G, Guida M, Sambiasi D and Colucci G: Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 17(Suppl 7): vii15-7, 2006.
24. Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H and Sjostrom-Mattson J: A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 7(5): 401-405, 2006. (Pubitemid 46157561)
25. Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G and Goldhirsch A: Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17(2): 322-329, 2006.
26. Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, Koralewski P, Mauriac L, Breton JL, Delozier T and Trillet-Lenoir V: Oral vinorelbine: feasibility and safety profile. Ann Oncol 12(12): 1677-1681, 2001.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000.
28. Variol P, Nguyen L, Tranchand B and Puozzo C: A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58(7): 467-476, 2002. (Pubitemid 35244920)
29. Delcambre C, Veyret C and Levy C: A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced breast cancer (MBC). In: Advances in the Treatment of Metastatic Breast Cancer: An Update From the San Antonio Breast Cancer Symposium 2005. San Antonio, Texas: Breast Cancer Res Treat; 2005.
30. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N and Villanova G: All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer 101(2): 232-237, 2009.
31. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M and Goldhirsch A: Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64(4): 673-680, 2009.